NDA 021618 · Mission Pharma
Tindamax
Tinidazole · Oral · Nitroimidazole Antimicrobial
NovelOrphanLast checked: Nov 20, 2026Latest source record: Dec 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
May 17, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
44
9 Phase 3, 2 recruiting
FAERS reports
435
314 serious, 20 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POTENTIAL RISK FOR CARCINOGENICITY WARNING: POTENTIAL RISK FOR CARCINOGENICITY Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent [see Nonclinical Toxicology (13.1)]. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use of TINIDAZOLE to approved indications only [see Indications and Usage (1.1, 1.2, 1.3)] . Avoid chronic use [see Warnings and Precautions (5.1)]. WARNING: POTENTIAL RISK FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent (13.1). Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use...
What it is approved for
From the label in effect Dec 1, 2025.
1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting...
Mechanism: Tinidazole is an antiprotozoal, antibacterial agent. [See Clinical Pharmacology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 21, 2007 Supplement 3 · Efficacy LabelLetter
- May 17, 2004 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
2 products under this application
- TINDAMAX · TINIDAZOLE 250MG · TABLET, ORAL · Prescription · TE AB
- TINDAMAX · TINIDAZOLE 500MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tinidazole" as an intervention, any sponsor and status, largest first.
- Study of the Management of Vaginal Discharge in West African Using Single Dose TreatmentsPivotal-lookingCompleted
Université de SherbrookeAcademic, hospital or other
NCT00313131 · 1,524 participants · Start Jan 2004
Drug: tinidazole+fluconazole vs metronidazole+clotrimazole · For: Bacterial Vaginosis; Candidiasis; Vaginitis
Sites: Accra, Ghana; Kumasi, Ghana; Conakry, Guinea · 7 sites in all
- Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori EradicationPivotal-lookingNot yet recruiting
University of Medicine and Pharmacy at Ho Chi Minh CityAcademic, hospital or other
NCT07746934 · 600 participants (planned) · Start Jul 27, 2026 · Primary completion Aug 27, 2027
Drug: Metronidazole; Tinidazole 500mg and 3 more · For: Helicobacter Pylori Infection
Sites: Ho Chi Minh City, Vietnam
- Treatment of Bacterial Vaginosis (BV) With TinidazolePivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00334633 · 593 participants · Start Nov 2004 · Primary completion Dec 2009
Drug: tinidazole, metronidazole · For: Bacterial Vaginosis
Sites: Birmingham, Alabama
- Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL OvulePivotal-lookingCompleted
Ege UniversityAcademic, hospital or other
NCT06056947 · 577 participants · Start Jul 20, 2020 · Primary completion May 6, 2021
Drug: EVEGYN A; EVEGYN B and 1 more · For: Trichomonal Vaginitis; Bacterial Vaginosis; Candidal Vulvovaginitis and 1 more
Sites: Izmir, Turkey (Türkiye)
- Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori TreatmentPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT02988089 · 480 participants (planned) · Start Apr 20, 2017 · Primary completion Sep 2017
Drug: Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ) and 4 more · For: Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
Sites: Ji'nan, China
- Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori InfectionPivotal-lookingCompleted
Shandong UniversityAcademic, hospital or other
NCT03658746 · 420 participants · Start Jan 1, 2019 · Primary completion Dec 31, 2019
Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); one proton pump inhibitor, colloidal bismuth pectin and 1 more · For: Helicobacter Pylori Infection
Sites: Jinan, China
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT03565484 · 400 participants (planned) · Start Jan 1, 2019 · Primary completion May 30, 2020
Drug: susceptibility guided therapy; personal medication history guided therapy and 1 more · For: Helicobacter Pylori Infection
Sites: Jinan, China
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.Pivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT03571230 · 400 participants (planned) · Start Jul 1, 2018 · Primary completion Dec 30, 2019
Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone) and 3 more · For: Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
Sites: Jinan, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective33
- nausea28
- off label use26
- pruritus26
- headache25
- diarrhoea22
- vomiting22
- pyrexia21
- rash21
- anxiety20
- neuropathy peripheral19
- paraesthesia19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 8 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 10 |
| 2010 | 11 |
| 2011 | 16 |
| 2012 | 18 |
| 2013 | 18 |
| 2014 | 25 |
| 2015 | 21 |
| 2016 | 31 |
| 2017 | 18 |
| 2018 | 27 |
| 2019 | 38 |
| 2020 | 49 |
| 2021 | 31 |
| 2022 | 24 |
| 2023 | 34 |
| 2024 | 12 |
| 2025 | 24 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amoebic dysentery.
Dans LF, Martínez EG · BMJ Clin Evid 2007 · Systematic Review
- Amoebic dysentery.
Marie C, Petri WA · BMJ Clin Evid 2013 · Systematic Review
- Amoebic dysentery.
Mackey-Lawrence NM, Petri WA · BMJ Clin Evid 2011 · Systematic Review
- Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
Mergenhagen KA, Wattengel BA, Skelly MK, et al. · Antimicrob Agents Chemother 2020 · Research Support, U.S. Gov't, Non-P.H.S., Systematic Review
- Antiamoebic drugs for treating amoebic colitis.
Gonzales MLM, Dans LF, Sio-Aguilar J · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Drugs for treating giardiasis.
Granados CE, Reveiz L, Uribe LG, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Systematic Review
Sponsor: Mission Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.